Potential five-year life years associated with stage IV reductions in NHS Galleri Trial
- 1Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine
Abstract
BackgroundNHS-Galleri did not reach its prespecified primary endpoint of a reduction in combined stage III and IV cases, but reported fewer stage IV cancers after annual multi-cancer early detection screening. We estimated the potential five-year life-years associated with the cancer-specific stage IV differences observed during the two incident screening rounds.
MethodsWe used intervention and control stage IV counts for ten prespecified cancers reported in the NHS-Galleri ASCO 2026 presentation. For each cancer, the randomized-arm count difference was multiplied by the difference in five-year restricted mean survival time between stage III and IV, estimated from England stage-specific five-year net survival using a constant-hazard fit. Adverse cancer-specific differences remained in the model. Results were annualized across the two incident rounds and scaled per million people screened. Sampling intervals used an independent Poisson approximation for arm-specific counts.
FindingsAcross the ten evaluable cancers, the intervention and control arms had 180 and 239 stage IV diagnoses during the incident rounds. The conditional projection was 66.3 potential life-years over five years in the trial intervention cohort, equivalent to 466 per million people screened annually (95% sampling interval 190-743). For a population of 10 million, the corresponding projection was 4,664 annually (1,896-7,432). Colorectal, lung, and esophageal cancers accounted for 79% of the net projection. Pancreatic, ovarian, and lymphoid cancers contributed negatively because their observed stage IV counts favored control.
InterpretationIf the observed incident-round reduction in stage IV diagnoses represents true downstaging to stage III, it could produce meaningful population health gains. This conditional estimate is not evidence of mortality reduction. Longer follow-up remains necessary to distinguish benefit from chance, lead-time and length biases, overdiagnosis, and differences in tumor biology.
Related
- Evaluation of the Diagnostic and Prognostic Potential, and Correlation with the Tumor Immune Microenvironment of a Six-miRNA Signature Associated with Platinum Sensitivity in Patients with Early-Stage Non-Small-Cell Lung Cancer
- Routes to Diagnosis and Stage at Diagnosis of Colorectal Cancer in Patients Aged ≥ 50 Years: A Multicentre Retrospective Cohort Study From North Wales, UK
- Are Increased Engagements With Recovery Support Services Associated With Reductions in Medicaid Billing Charges and Reimbursements?
- Differential Enteric Glial and Mast Cell Characteristics Distinguish Microscopic Colitis Subtypes Relative to Healthy and Disease Controls, with Treatment-Associated Reductions in Glial Reactivity and Mast Cell Degranulation in Collagenous Colitis.
- Twenty-one years of cutaneous melanoma: stage shift, anatomical patterns and diagnostic trends from a Southern European tertiary center
BibTeX
@misc{starasvetskaya2026potential,
title = {{Potential five-year life years associated with stage IV reductions in NHS Galleri Trial}},
author = {N. Starasvetskaya and G. de Lima Lopes Junior},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.21.26363618},
url = {https://www.medrxiv.org/content/10.64898/2026.09.21.26363618v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Potential five-year life years associated with stage IV reductions in NHS Galleri Trial
AU - N. Starasvetskaya
AU - G. de Lima Lopes Junior
PY - 2026
DA - 2026/09/21
PB - medRxiv
DO - 10.64898/2026.09.21.26363618
UR - https://www.medrxiv.org/content/10.64898/2026.09.21.26363618v1
AB - BackgroundNHS-Galleri did not reach its prespecified primary endpoint of a reduction in combined stage III and IV cases, but reported fewer stage IV cancers after annual multi-cancer early detection screening. We estimated the potential five-year life-years associated with the cancer-specific stage IV differences observed during the two incident screening rounds. MethodsWe used intervention and control stage IV counts for ten prespecified cancers reported in the NHS-Galleri ASCO 2026 presentation. For each cancer, the randomized-arm count difference was multiplied by the difference in five-year restricted mean survival time between stage III and IV, estimated from England stage-specific five-year net survival using a constant-hazard fit. Adverse cancer-specific differences remained in the model. Results were annualized across the two incident rounds and scaled per million people screened. Sampling intervals used an independent Poisson approximation for arm-specific counts. FindingsAcross the ten evaluable cancers, the intervention and control arms had 180 and 239 stage IV diagnoses during the incident rounds. The conditional projection was 66.3 potential life-years over five years in the trial intervention cohort, equivalent to 466 per million people screened annually (95% sampling interval 190-743). For a population of 10 million, the corresponding projection was 4,664 annually (1,896-7,432). Colorectal, lung, and esophageal cancers accounted for 79% of the net projection. Pancreatic, ovarian, and lymphoid cancers contributed negatively because their observed stage IV counts favored control. InterpretationIf the observed incident-round reduction in stage IV diagnoses represents true downstaging to stage III, it could produce meaningful population health gains. This conditional estimate is not evidence of mortality reduction. Longer follow-up remains necessary to distinguish benefit from chance, lead-time and length biases, overdiagnosis, and differences in tumor biology.
ER -